Cel Sci

The Ultimate Guide to Building a Sustainable Morning Routine in 2025

Thu, 21 Nov 2024 20:42:00 +0000

Introduction: Why Your Morning Routine Matters

Do you ever feel like your mornings set the tone for your entire day? You’re not alone. Research shows that a well-structured morning routine can significantly impact your productivity, mental health, and overall well-being. But here’s the catch: not all morning routines are created equal.

In 2025, the focus has shifted toward building sustainable morning routines—habits that are not only effective but also realistic and adaptable to your lifestyle. Forget the cookie-cutter advice of waking up at 4:30 AM or drinking celery juice (unless that’s your thing). This guide will help you craft a morning routine that works for YOU, using science-backed strategies and practical tips.

What Is a Sustainable Morning Routine?

A sustainable morning routine is one that you can stick to long-term without feeling overwhelmed or burnt out. It’s not about perfection; it’s about consistency and balance.

Key Elements of a Sustainable Morning Routine

Personalization: Your routine should reflect your unique goals, energy levels, and lifestyle.
Flexibility: Life happens. A good routine allows for adjustments without guilt.
Balance: Incorporate activities that nurture your mind, body, and soul.

The Science Behind Morning Routines

Why do morning routines work? It all comes down to psychology and biology.

The Power of Habit Formation

Morning routines leverage the brain’s natural tendency to form habits. When you repeat the same actions daily, they become automatic, freeing up mental energy for more complex tasks.

The Role of Cortisol

Cortisol, often called the “stress hormone,” peaks in the morning. A structured routine can help regulate cortisol levels, reducing stress and improving focus.

How to Build Your Perfect Morning Routine

Ready to design a morning routine that sticks? Follow these steps:

1. Start with a Clear Intention

Ask yourself: What do I want to achieve with my mornings? Whether it’s boosting productivity, improving mental health, or simply enjoying some “me time,” your intention will guide your routine.

2. Prioritize Sleep

A great morning starts the night before. Aim for 7–9 hours of quality sleep to wake up refreshed and ready to tackle the day.

3. Choose 3–5 Core Activities

Focus on a few key activities that align with your goals. Here are some ideas:

Mindfulness: Meditation, journaling, or deep breathing exercises.
Movement: Stretching, yoga, or a quick workout.
Nourishment: A healthy breakfast or a glass of water with lemon.
Planning: Reviewing your to-do list or setting daily priorities.

4. Keep It Short and Sweet

Your morning routine doesn’t need to be an hour long. Even 15–30 minutes can make a difference. The key is consistency.

5. Test and Tweak

No routine is perfect from the start. Experiment with different activities and timings until you find what works best for you.

Common Morning Routine Mistakes to Avoid

Even the best intentions can go awry. Here are some pitfalls to watch out for:

Overloading Your Routine: Trying to do too much can lead to burnout.
Skipping Weekends: Consistency is key, even on weekends.
Comparing Yourself to Others: Your routine should be tailored to YOU, not Instagram influencers.

Real-Life Example: A 30-Minute Morning Routine

Here’s a sample routine to inspire you:

6:30 AM: Wake up and drink a glass of water.
6:35 AM: Stretch or do 5–10 minutes of yoga.
6:45 AM: Spend 5 minutes journaling or meditating.
6:50 AM: Eat a light, nutritious breakfast.
7:00 AM: Review your goals or to-do list for the day.

Conclusion: Start Your Day, Your Way

A sustainable morning routine is one of the best investments you can make in yourself. It doesn’t have to be complicated or time-consuming—it just needs to work for you. By focusing on consistency, personalization, and balance, you can create a routine that sets you up for success every single day.

So, what are you waiting for? Start small, stay consistent, and watch your mornings (and your life) transform.

casino siteleri
bahis siteleri
marsbahis giris
stake giris
1xbet giris
grandpashabet giris
casibom giris
deneme bonusu
deneme bonusu veren siteler
guvenilir bahis siteleri
guvenilir slot siteleri
casino siteleri
bahis siteleri
marsbahis giris
stake giris
1xbet giris
grandpashabet giris
casibom giris
deneme bonusu
deneme bonusu veren siteler
guvenilir bahis siteleri
guvenilir slot siteleri
casino siteleri
bahis siteleri
marsbahis giris
stake giris
1xbet giris
grandpashabet giris
casibom giris
deneme bonusu
deneme bonusu veren siteler
guvenilir bahis siteleri
guvenilir slot siteleri
canli casino Deneme Bonusu Slot Siteleri

Micah Parsons Trade Rumors: What’s Next for the Cowboys Star?

Mon, 02 Sep 2024 00:02:00 +0000

The NFL rumor mill is buzzing with speculation surrounding Dallas Cowboys linebacker Micah Parsons. Recent surges in searches for terms like “Micah Parsons trade request,” “Micah Parsons contract,” and “Micah Parsons landing spots” have fans and analysts questioning the star’s future in Dallas. Let’s break down the situation.

The Trade Rumor Storm

Keywords like “Micah Parsons trade,” “Micah Parsons trade rumors,” and “did Micah Parsons request a trade” have dominated NFL news cycles. While Parsons himself hasn’t publicly demanded a move, whispers persist about potential friction. Cowboys executives Jerry Jones and Stephen Jones have addressed these rumors, emphasizing Parsons’ value to the team. Yet, searches for “Micah Parsons requesting trade” and related phrases suggest fans remain concerned.

Contract Concerns

Parsons’ rookie contract is approaching a critical juncture, driving intense interest in “Micah Parsons contract” details. As one of the league’s elite defenders, he’s poised for a massive extension. The Cowboys also face decisions on other stars like CeeDee Lamb (reflected in “CeeDee Lamb contract” searches), creating salary cap complexities. This financial backdrop fuels speculation about whether Dallas can afford its core talent long-term.

Potential Landing Spots

If a trade were to occur, where could Parsons land? Searches for “Micah Parsons next team odds” and “Micah Parsons landing spots” point to several possibilities:

Chicago Bears: A young, ascending team with cap space and defensive needs (“Chicago bears” trends high).
Philadelphia Eagles: NFC East rivals with aggressive management (Howie Roseman) and a win-now mentality (“Micah Parsons eagles” appears frequently).
Buffalo Bills: A contender needing an edge presence (“Buffalo bills” shows consistent interest).
Seattle Seahawks: Another franchise with defensive aspirations (“Seahawks” appears in related searches).

The Cowboys’ Dilemma

Dallas faces a crossroads. Parsons is a generational talent, but keeping him requires significant financial commitment. The front office must weigh his value against other priorities like extending Dak Prescott and rebuilding the defense. Searches for “Stephen Jones Cowboys” and “Jerry Jones” reflect fan scrutiny of their decision-making.

What Parsons Says

On social media (driving “Micah Parsons Twitter” searches), Parsons has remained largely professional but hasn’t shied away from competitive fire. His comments about wanting to win could be interpreted as subtle pressure if the team doesn’t improve around him.

The Verdict

While “Micah Parsons trade request” remains speculation, the confluence of contract timing, team dynamics, and Parsons’ elite status makes this a legitimate storyline. For now, he remains a Cowboy, but the NFL landscape can shift quickly. Fans should monitor credible sources like Yahoo Sports for verified updates rather than rumors.

Jojobet Giriş
Casibom Giriş
Grandpashabet Giriş
Casino Siteleri
Deneme Bonusu
Deneme Bonusu
1xbet Giriş
Grandpashabet Giriş
Casibom Giriş
Deneme Bonusu
Deneme Bonusu
Güvenilir Bahis Siteleri
Güvenilir Bahis Siteleri
Casino Siteleri
Bahis Siteleri
Marsbahis Giriş
Stake Giriş
1xbet Giriş
Grandpashabet Giriş
Casibom Giriş
Deneme Bonusu
Deneme Bonusu
Güvenilir Bahis Siteleri
Güvenilir Bahis Siteleri
Casino Siteleri
Bahis Siteleri
Marsbahis Giriş
Stake Giriş
1xbet Giriş
Grandpashabet Giriş
Casibom Giriş
Deneme Bonusu
Deneme Bonusu
Güvenilir Bahis Siteleri
Güvenilir Bahis Siteleri
Canlı Casino
Deneme Bonusu
Slot Siteleri

The Fall of the Western Roman Empire: A Singular Cause or a Multifaceted Process?

Wed, 21 Aug 2024 23:43:00 +0000

Introduction

The year 476 CE, when the last Western Roman Emperor, Romulus Augustulus, was deposed by the Germanic chieftain Odoacer, serves as the symbolic end of the Western Roman Empire. This event has long been the subject of intense historical debate. While 18th-century historian Edward Gibbon famously attributed the decline to internal decay and the rise of Christianity, modern scholarship largely dismisses a singular cause, instead highlighting a complex interplay of political, economic, social, and military factors that accumulated over several centuries. This essay will analyze these diverse factors to argue that the fall of Rome was not a sudden collapse but a protracted process of transformation.

Internal Factors: Political and Economic Collapse

The seeds of the empire’s decline were sown during the Crisis of the Third Century, a period of extreme political instability marked by frequent assassinations of emperors, civil wars, and a breakdown of central authority. The average reign of an emperor was short, and many were preoccupied with securing their power rather than governing effectively. This led to a decentralization of power, with provincial governors and military commanders gaining greater autonomy. The massive military expenditures required to defend the empire and fund these civil wars placed an immense financial burden on the state.

Economic problems were a major catalyst for the decline. The cessation of imperial expansion meant an end to the influx of new resources and, critically, slaves. This undermined the slave-based agricultural economy that had been the foundation of Roman prosperity. Trade routes became increasingly insecure, leading to inflation and a debasement of the currency. The wealthy landowning elite (latifundia) consolidated vast estates, forming private armies and becoming self-sufficient, thereby evading imperial taxes. This economic and political fragmentation deeply weakened the empire from within.

Military and External Factors: Barbarian Invasions and the Army

The fall of the empire is often most visibly linked to the invasions of various Germanic tribes, such as the Goths, Vandals, and Franks. Beginning in the late 4th century, these tribes, pressured by the Huns, migrated en masse towards the empire’s borders. The Roman army, once the symbol of its might, was overstretched and increasingly relied on non-Roman mercenaries. These soldiers often held greater loyalty to their own tribes or commanders than to the Roman state, compromising the army’s integrity.

A psychological turning point was the Sack of Rome by the Visigoths under Alaric in 410 CE, an event that shattered the myth of the city’s invincibility. This was followed by the devastating Sack of Rome by the Vandals in 455 CE. These invasions led to the loss of crucial provinces like Britannia, Gaul, and Hispania, which became independent Germanic kingdoms. This loss of territory further crippled the empire’s tax base and ability to raise a proper army, leaving Rome’s control largely confined to the Italian peninsula.

Social and Cultural Transformations

The decline of the empire was also accompanied by a significant social and cultural shift. Urban life declined as populations migrated to rural areas, seeking protection and sustenance on large, fortified estates. These villas became the new centers of economic and social life, further eroding the authority of the central government. The rise of Christianity also played a key role. The Church filled the power vacuum left by the decaying imperial structure, providing a new source of authority, social cohesion, and welfare services in a time of crisis. While some historians argue that the Church’s focus on the spiritual rather than the temporal weakened civic loyalty to the state, the more prevailing view is that it provided stability and continuity in a period of chaos.

Conclusion

The collapse of the Western Roman Empire was not the result of a single catastrophic event but rather a long-term process fueled by the interplay of internal and external pressures. Political instability, economic decline, a weakened military, and the constant pressure from migrating barbarian tribes all contributed to the gradual erosion of imperial authority and territory. The year 476 CE was merely the final, symbolic act of a structure that had been collapsing for centuries. The fall of the West marked the end of an era and the beginning of the Middle Ages, laying the groundwork for the formation of the modern nation-states of Europe. The legacy of Roman law, language, and culture persisted, most notably in the continuation of the Eastern Roman (Byzantine) Empire for another thousand years, demonstrating that Rome’s influence did not simply vanish but was transformed. The fall of Rome should therefore be viewed not as a finality, but as a pivotal transition in human history.

The Secrets to Being a Trustworthy News Source in the Digital Age

Thu, 11 Jan 2024 22:53:00 +0000

In today’s information-bombarded era, we’re exposed to an endless stream of news and information daily. From social media platforms to news websites, blogs, and countless other sources, navigating this dense flow to find reliable and accurate information has become more crucial than ever. As a WordPress news site owner, your biggest responsibility is to provide your readers with content that is not only current but also fact-checked and unbiased. So, how can you stand out in this highly competitive environment, earn your readers’ trust, and make your site an indispensable source of information?

1. Accuracy and Source Verification: The Cornerstone

A news website’s most valuable asset is its credibility. You must meticulously research and verify the sources for every piece of news you publish. Cross-referencing information with multiple independent sources is the most effective way to ensure accuracy. Especially when faced with rapidly spreading dubious information or “fake news,” it’s critical to adhere to journalistic ethics and avoid speculation. Your readers will trust you more when they know your site consistently delivers accurate information.

2. Impartiality and Balanced Perspectives

As a news site, maintaining an impartial stance helps readers understand different perspectives. When presenting news, you should set aside personal opinions or biases. Fairly representing all sides in controversial topics gives your readers the opportunity to understand the complete picture. This not only enhances the objectivity of the news but also elevates your site’s reputation.

3. In-depth Analysis and Comprehensive Content

Simply answering “what happened” isn’t enough. Your readers are also curious about the reasons, consequences, and potential impacts of an event. By supporting your news with in-depth analyses, you offer your readers an understanding beyond superficial information. Including expert opinions, and visualizing information with statistics and graphs, will increase the impact and value of your news. This kind of comprehensive content encourages readers to spend more time on your site and return repeatedly.

4. Transparency and Editorial Policies

Clearly stating your site’s editorial policies demonstrates your transparency to readers. Admitting and correcting mistakes when they occur is an important part of building trust. Providing readers with information about your news gathering processes, source usage, and verification methods strengthens your site’s credibility.

5. Reader Engagement and Feedback

Engaging with your readers and considering their feedback contributes to your site’s development. Allow readers to express their thoughts by keeping comment sections open or organizing surveys. Approaching criticism constructively and evaluating suggestions will help you build a stronger bond with your readership. This way, you can shape your site according to your readers’ needs.

Being a trustworthy news source in the digital age is a process that requires continuous effort and care. However, by adopting and applying these principles, you can transform your WordPress news site from just an information platform into an indispensable address for trust and accuracy for the community. Remember, the need for accurate information is greater than ever, and meeting that need is in your hands.

Deneme Bonusu
Canlı Casino
Bahis Siteleri
Deneme bonusu veren siteler
Canlı Casino Siteleri

Fenerbahçe vs Feyenoord: Which Channel, Live Stream, and How to Watch the Match

Tue, 12 Jul 2022 21:14:00 +0000

The highly anticipated Fenerbahçe – Feyenoord clash in the UEFA Champions League third qualifying round is creating a wave of excitement among football fans. Supporters are already searching for Fenerbahçe Feyenoord hangi kanalda, live match watch, and Selçuk Sports canlı maç izle to find out where and how they can enjoy the game. This second leg will be decisive, as Fenerbahçe looks to secure their place in the next round after a tight first match.

Match Date, Time, and Venue

The Fenerbahçe vs Feyenoord match will take place on Tuesday, August 12, 2025, with kick-off scheduled for 20:00 (8:00 PM local time). The game will be played at the Ülker Stadyumu in Istanbul, Turkey. Fans in different time zones should adjust accordingly to avoid missing a single minute of action.

Which Channel Will Broadcast the Match?

For fans asking Fenerbahçe maçı hangi kanalda (“which channel is the match on”), here is the confirmed list for Turkey:

TRT 1 (Free-to-air in Turkey)
TRT Spor (Free-to-air sports channel)
EXXEN (Online streaming with Sports Package subscription)

The EXXEN Sports Package is required for streaming the match online. Unfortunately, EXXEN does not currently offer a single match purchase option, meaning you must subscribe to watch.

Is the Match Available Free or “Şifresiz”?

Many fans are searching for Fenerbahçe Feyenoord maçı şifresiz mi (is the match free to watch). In Turkey, the match will not be available fully free on digital platforms; however, TRT 1 and TRT Spor will broadcast it on television without additional cost. Online streaming via EXXEN requires a paid subscription.

In other countries, broadcasting rights vary. Some European broadcasters may show the game free-to-air, including RTL (Germany, Luxembourg), RTÉ (Ireland), Channel 4 (UK), Antena 3 (Spain), and TV3 (Sweden). Always check your local listings for confirmation.

What About “Selçuk Sports” and Online Streams?

The term Selçuk Sports canlı maç izle is widely searched, but it is not an official channel. It often appears on fan forums and social media as a slang reference to certain unofficial streaming websites. Viewers should be aware that these are not authorized UEFA broadcasters and may not provide reliable or legal access to the match.

For a high-quality and legal stream, EXXEN remains the official online platform in Turkey. Subscribing to the EXXEN Sports Package ensures you get uninterrupted, HD coverage of Fenerbahçe – Feyenoord.

Possible Lineups and Key Players

Fenerbahçe is expected to field a strong starting XI, possibly featuring attacking threats like Edin Džeko and Dusan Tadić, along with creative midfield playmakers. Feyenoord, on the other hand, will rely on speed and precision from players like Santiago Giménez and Calvin Stengs. Fans will also be watching closely for contributions from former Fenerbahçe star Robin van Persie, now part of Feyenoord’s coaching setup.

Summary Table: Match Details

Detail	Information
Match	Fenerbahçe – Feyenoord
Date	Tuesday, August 12, 2025
Time	20:00 (8 PM local time)
Venue	Ülker Stadyumu, Istanbul
Channels in Turkey	TRT 1, TRT Spor, EXXEN (Sports Package required)
Free-to-air (“Şifresiz”)	Yes on TV (TRT 1 & TRT Spor), No for online streaming
Official Online Stream	EXXEN Sports Package
Unofficial References	“Selçuk Sports” (not an official broadcaster)

Final Word

If you are a Fenerbahçe supporter eager to catch the Fenerbahçe – Feyenoord match live, your best options in Turkey are TRT 1 and TRT Spor on TV, or EXXEN Sports Package for online streaming. For those abroad, check your local sports channels to see if the match is available in your region. Whether you watch on TV or online, this is a match no football fan will want to miss.

Casibom Giriş
Casibom Giriş
Casibom Giriş
Casibom Giriş
Casibom Giriş
Grandpashabet Giriş
Grandpashabet Giriş
Grandpashabet Giriş
Grandpashabet Giriş
Grandpashabet Giriş
MobilBahis Giriş
Mobilbahis Giriş
Mobilbahis Giriş
Mobilbahis Giriş
Mobilbahis Giriş
Justin TV Giriş
Justin TV Giriş
Justin TV Giriş
Betnano Giriş
Bet365 Giriş
Klasbahis Giriş
Biabet Giriş
Biabet Giriş
Biabet Giriş
Betebet Giriş
Pusulabet Giriş
Festwin Giriş
Cenabet Giriş
Mavibet Giriş
Matadorbet Giriş
Holiganbet Giriş
Bet365 Giriş
Tipobet Giriş
Marsbahis Giriş
Stake Giriş
Stake Giriş
Stake Giriş

The Ultimate Guide to Live Betting Games

Mon, 23 May 2022 00:02:00 +0000

Introduction to Live Betting Games

Live betting games, also known as in-play betting, have revolutionized the online gambling industry. Unlike traditional betting, where wagers are placed before the event begins, live betting allows players to place bets during the game or event. This dynamic and interactive form of betting has gained immense popularity among sports enthusiasts and casino players alike.

In this comprehensive guide, we will explore the world of live betting games, their advantages, strategies for success, and tips to enhance your overall experience.

How Do Live Betting Games Work?

Live betting operates in real-time, meaning that the odds and betting options change dynamically as the game progresses. For example, in a football match, you can bet on the next goal scorer, the outcome of the first half, or even the total number of goals scored. Similarly, in live casino games, you can place bets on outcomes like roulette spins or blackjack hands as they happen.

To participate in live betting, players need to have a stable internet connection and access to a reliable betting platform. Most platforms offer live streaming of events, allowing players to watch the action unfold while placing their bets.

Advantages of Live Betting

Live betting offers several unique advantages that set it apart from traditional betting:

Real-Time Engagement: The ability to place bets during the game keeps players engaged and adds an extra layer of excitement.
Dynamic Odds: Since the odds change based on the current state of the game, players can take advantage of favorable odds at the right moment.
Informed Decisions: Watching the game live allows players to make more informed decisions based on the performance of teams or players.
Variety of Betting Options: Live betting offers a wide range of options, from predicting the next play to betting on specific outcomes.

Popular Types of Live Betting Games

Live betting is not limited to just one type of game. Here are some of the most popular categories:

1. Live Sports Betting

Sports betting is the most common form of live betting. Players can bet on football, basketball, tennis, cricket, and more. Common bets include predicting the next goal, the final score, or the performance of individual players.

2. Live Casino Games

Live casino games bring the thrill of a real casino to your screen. Popular games include live roulette, blackjack, baccarat, and poker. These games are hosted by real dealers and streamed in high definition.

3. Esports Live Betting

With the rise of esports, live betting on competitive gaming events has become increasingly popular. Players can bet on games like League of Legends, Dota 2, and Counter-Strike: Global Offensive.

Strategies for Successful Live Betting

While live betting is exciting, it also requires a strategic approach. Here are some tips to improve your chances of success:

Research Thoroughly: Before placing any bets, research the teams, players, and their recent performance. Knowledge is power in live betting.
Start Small: If you’re new to live betting, start with smaller bets to get a feel for how it works.
Stay Calm: Live betting can be fast-paced and intense. Avoid making impulsive decisions and stick to your strategy.
Use Cash-Out Options: Many platforms offer cash-out options, allowing you to secure your winnings or minimize losses before the event ends.
Set Limits: Always set a budget and stick to it. Responsible gambling is key to enjoying the experience.

Conclusion

Live betting games offer an unparalleled level of excitement and engagement for players. Whether you’re a sports enthusiast or a casino lover, live betting provides endless opportunities to test your skills and intuition. By understanding the dynamics of live betting, leveraging strategies, and betting responsibly, you can enhance your experience and increase your chances of success.

So why wait? Dive into the world of live betting today and experience the thrill of real-time action!

CEL-SCI REPORTS RECENT DATA REVIEW BY THE INDEPENDENT DATA MONITORING COMMITTEE FOR ITS PIVOTAL PHASE 3 HEAD AND NECK CANCER STUDY

brandonschwartz32@gmail.com — Mon, 22 Oct 2018 02:59:28 +0000

CEL-SCI REPORTS RECENT DATA REVIEW BY THE INDEPENDENT DATA MONITORING COMMITTEE FOR ITS PIVOTAL PHASE 3 HEAD AND NECK CANCER STUDY

Vienna, VA, August 15, 2018 — CEL-SCI Corporation (NYSE American: CVM)announced today that the Independent Data Monitoring Committee (IDMC) for the Company’s pivotal Phase 3 head and neck cancer study of its investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection) has completed its recent review of the Phase 3 study data. The data from all 928 enrolled patients were provided to the IDMC by the clinical research organization (CRO) responsible for data management of this Phase 3 study.

The IDMC made the following recommendation:

The IDMC recommendation is to continue the trial until the appropriate number of events have occurred.

IDMCs are committees commonly used by sponsors of clinical trials to protect the interests of the patients and the integrity of the study data in ongoing trials, especially when the trials involve patients with life threatening diseases, and when, as in cancer clinical trials, they extend over long periods of time.

About CEL-SCI Corporation

CEL-SCI believes that boosting a patient’s immune system while it is still intact should provide the greatest possible impact on survival. Therefore, in the Phase 3 study CEL-SCI treats patients who are newly diagnosed with advanced primary squamous cell carcinoma of the head and neck with Multikine first, BEFORE they receive surgery, radiation and/or chemotherapy. This approach is unique. Most other cancer immunotherapies are administered only after conventional therapies have been tried and/or failed. Multikine (Leukocyte Interleukin, Injection), has received Orphan Drug designation from the FDA for the neoadjuvant therapy in patients with squamous cell carcinoma (cancer) of the head and neck.

CEL-SCI’s Phase 3 study is the largest Phase 3 study in the world for the treatment of head and neck cancer. Per the study’s protocol, newly diagnosed patients with advanced primary squamous cell carcinoma are treated with the Multikine treatment regimen for 3 weeks prior to the Standard of Care (SOC) which involves surgery, chemotherapy and/or radiation. Multikine is designed to help the immune system “see” the tumor at a time when the immune system is still relatively intact and thereby better able to mount an attack on the tumor. The aim of treatment with Multikine is to boost the body’s immune system prior to SOC.

The Company’s LEAPS technology is currently being developed as a therapeutic vaccine for rheumatoid arthritis and is supported by grants from the National Institutes of Health. The Company has operations in Vienna, Virginia, and in/near Baltimore, Maryland.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. When used in this press release, the words “intends,” “believes,” “anticipated,” “plans” and “expects,” and similar expressions, are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Factors that could cause or contribute to such differences include an inability to duplicate the clinical results demonstrated in clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company’s potential products, inability to raise the necessary capital and the risk factors set forth from time to time in CEL-SCI’s filings with the Securities and Exchange Commission, including but not limited to its report on Form 10-K for the year ended September 30, 2017. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

* Multikine (Leukocyte Interleukin, Injection) is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with the Company’s future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or any other regulatory agency. Similarly, its safety or efficacy has not been established for any use. Moreover, no definitive conclusions can be drawn from the early-phase, clinical-trials data involving the investigational therapy Multikine. Further research is required, and early-phase clinical trial results must be confirmed in the Phase 3 clinical trial of this investigational therapy that is in progress.

CEL-SCI ANNOUNCES THAT THE NYSE AMERICAN APPROVES PLAN

brandonschwartz32@gmail.com — Mon, 22 Oct 2018 02:58:52 +0000

CEL-SCI ANNOUNCES THAT THE NYSE AMERICAN APPROVES PLAN

Vienna, VA, August 17, 2018 — CEL-SCI Corporation (NYSE American: CVM)announces that the NYSE American (the “Exchange”) has accepted the Company’s plan to bring itself into compliance with the Exchange’s continued listing standards.

The Company previously received notice from the Exchange on July 12, 2018, indicating the Company is below compliance with Section 1003(a)(i), Section 1003(a)(ii) and Section 1003(a)(iii) since it reported a stockholders’ equity deficit as of June 30, 2018 and had net losses in its 5 most recent fiscal years ended September 30, 2017. Additional information and provisions regarding the NYSE American requirements are found in Part 10 of its Company Guide. The Company was afforded the opportunity to submit a plan to regain compliance, and on July 30, 2018 the Company submitted its plan to the Exchange.

On August 16, 2018 the Exchange notified the Company that it accepted the Company’s plan of compliance and granted the Company until January 14, 2019 to regain compliance with the continued listing standards. The Company will be subject to periodic review during this period. Failure to make progress consistent with the plan or to regain compliance with the continued listing standards by the end of the period could result in the Company being delisted from the NYSE American. The Company may then appeal a staff determination to initiate such proceedings in accordance with the exchange’s Company Guide.

“We are very pleased that the NYSE American has accepted our compliance plan. Continued listing on the NYSE American is highly beneficial to CEL-SCI and its shareholders and we look forward to regaining full compliance,” stated CEL-SCI CEO Geert Kersten.

About CEL-SCI Corporation

Forward-Looking Statements

CEL-SCI CORPORATION RELEASES LETTER TO SHAREHOLDERS

brandonschwartz32@gmail.com — Mon, 22 Oct 2018 02:58:22 +0000

Vienna, VA, August 21, 2018 — The following letter was sent by CEL-SCI Corporation (NYSE American: CVM) to its shareholders for the upcoming annual meeting:

Dear CEL-SCI Shareholders,

Our singular goal right now is to reach the final data readout of the Phase 3 trial to establish the utility of our investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection) in the treatment of head and neck cancer. Enrollment was completed in September of 2016. Based on published survival data, we believe top line results may be available as soon as early 2019.

The results of the Phase 3 study, if positive, will form the basis of our regulatory submissions for marketing applications worldwide to commercially market and distribute Multikine. The U.S. FDA has not approved a new drug for advanced primary squamous cell carcinoma (cancer) of the head and neck in about 60 years, a clear unmet medical need. The FDA has granted Multikine Orphan Drug status in this indication.

If we receive FDA approval, we believe that Multikine should become part of the standard of care (SOC) because the study endpoint of “improvement in overall survival” is the gold standard for cancer drug approval. Since our Phase 3 head and neck cancer study is the largest head and neck cancer study ever conducted, we expect data from it should be sufficiently robust and highly regarded to support our belief. Multikine should then become the recommended first treatment to be administered following diagnosis of cancer and before SOC is administered, for a cancer that affects about 650,000 patients per year.

This key inflection point is on the near term horizon. CEL-SCI is a cancer immunotherapy company that has a market cap of about $20 million. That makes little sense. We think that this is in large part due to the fact that we have all been waiting for Phase 3 data for 8.5 years. That is a long time. But, the last patients were enrolled almost two years ago and the final read out of the Phase 3 study is near. In the past 18 months, several successful Phase 3 cancer immunotherapy companies were sold for $7 billion to almost $12 billion. They had positive survival data from their pivotal studies, but had not yet received FDA approval. In addition, recently one cancer immunotherapy company with Phase 3 studies that were not yet complete was sold for about $1.6 billion.

CEL-SCI’s Multikine Phase 2 open label “Proof of Concept” study used the same three week Multikine treatment regimen prior to SOC that is being used in the current Phase 3 study. The effects of a 3 week Multikine treatment regimen on the tumors that were removed at surgery (per SOC) following the Multikine treatment regimen was examined and evaluated by pathology. The findings were published in the Journal of Clinical Oncology and presented at American Society of Clinical Oncology. The pathologists found that about 10% of patients had no tumor cells remaining after a three week Multikine treatment, and the remaining patients had only about 50% of their tumor cells remaining. In a survival follow-up study of patients from the same Phase 2 study, it was determined that there was a 33% overall survival benefit compared to results obtained in 55 clinical trials reported in the scientific literature between 1987 and 2007 in the same patient population (Advanced Primary Squamous Cell Carcinoma of the Head and Neck). Our pivotal Phase 3 study is designed to prove a 10% overall survival benefit in a prospectively controlled study in a statistically significant manner.

Our idea and aim is to help cancer patients by boosting their immune system BEFORE the ravages of surgery, radiation and chemotherapy. We believe that boosting a cancer patient’s immune system while it is still intact, before surgery and/or radiation/chemotherapy, should provide the greatest possible impact on survival. Our Phase 3 study is meant to prove this. This is a logical concept and one that made sense to 24 regulatory agencies, including the FDA, when we applied to them to conduct this global Phase 3 study. This idea is now gaining traction among oncologists. If we are successful in head and neck cancer, we hope to expand this concept to other cancers.

We recently completed and won the arbitration against the clinical research organization (CRO) that ran our Phase 3 head and neck cancer study from 2011-2013. The arbitrator ruled that the CRO materially breached its contract with CEL-SCI. The arbitrator’s decision has vindicated us. Many investment funds and analysts did not like the legal risk of this arbitration and now that the arbitration has been resolved in our favor, this should no longer be an impediment to investors and should result in renewed investment interest in CEL-SCI. With the arbitration behind us, we move forward with a clean slate.

Investors, new and old, can now focus on the achievements that establish the true value of our Company: 1) a fully enrolled cancer Phase 3 clinical trial awaiting final top line data readout; and 2) a very promising rheumatoid arthritis treatment vaccine candidate, based on our LEAPS technology, funded by a large U.S. government grant.

Moving forward to a promising future, we plan to meet with and provide an update to interested investors, many of whom will be looking at CEL-SCI for the first time.

Sincerely,

Geert Kersten
Chief Executive Officer

Forward-Looking Statements

This shareholder letter contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. When used in this press release, the words “intends,” “believes,” “anticipated,” “plans” and “expects,” and similar expressions, are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Factors that could cause or contribute to such differences include, an inability to duplicate the clinical results demonstrated in clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company’s potential products, inability to raise the necessary capital and the risk factors set forth from time to time in CEL-SCI’s filings with the Securities and Exchange Commission, including but not limited to its report on Form 10-K for the year ended September 30, 2017. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

NIH SELECTS CEL-SCI’s LEAPS RHEUMATOID ARTHRITIS VACCINE FOR COMMERCIALIZATION ACCELERATOR PROGRAM

brandonschwartz32@gmail.com — Mon, 22 Oct 2018 02:57:50 +0000

Vienna, VA, September 5, 2018 — CEL-SCI Corporation (NYSE American: CVM) announced today that the National Institutes of Health (NIH) selected CEL-SCI and its LEAPS* rheumatoid arthritis vaccine candidate as a Small Business Innovation Research/Small Business Technology Transfer (SBIR/STTR) Commercialization Accelerator Program Phase II awardee for 2018-2019. LEAPS has been specifically selected by the NIH for the Commercialization Transition Track, which provides technical assistance to awardee companies to move NIH-funded technologies towards commercialization and market readiness.

CEL-SCI was eligible and applied for the Commercialization Accelerator Program as part of its $1.5 million Phase II SBIR/STTR NIH grant to develop its LEAPS rheumatoid arthritis vaccine. Only a select number of the SBIR Phase II awarded companies are also accepted into the Commercialization Accelerator Program by the NIH.

“We are pleased that the NIH has selected CEL-SCI and our LEAPS rheumatoid arthritis vaccine candidate for this important commercialization program. We believe the NIH’s program will support and accelerate LEAPS’s advancement into clinical studies and towards commercialization. Preclinical data have shown that LEAPS vaccines may be advantageous to other therapies because LEAPS acts early on the immune system to inhibit the production of disease-promoting inflammatory cytokines,” stated Dr. Daniel Zimmerman, Senior Vice President of Research, Cellular Immunology of CEL-SCI.

About Rheumatoid Arthritis

Rheumatoid Arthritis is a chronic inflammatory disease that mainly targets the synovial membrane, cartilage and bone. It affects about 1% of the global population and is associated with significant morbidity and increased mortality. Anti-TNF related therapies are the current standard treatment of patients with advanced RA, but over half of the RA patients do not respond well to current anti-TNF drugs such as etanercept (Enbrel®) and infliximab (Remicade®).

About CEL-SCI Corporation

CEL-SCI believes that boosting a patient’s immune system while it is still intact should provide the greatest possible impact on survival. Therefore, in the Phase 3 study CEL-SCI treats patients who are newly diagnosed with advanced primary squamous cell carcinoma of the head and neck with Multikine** right after diagnosis, BEFORE they receive surgery, radiation and/or chemotherapy. This approach is unique. Most other cancer immunotherapies are administered only after conventional therapies have been tried and/or failed. Multikine (Leukocyte Interleukin, Injection), has received Orphan Drug designation from the FDA for the neoadjuvant therapy in patients with squamous cell carcinoma (cancer) of the head and neck.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. When used in this press release, the words “intends,” “believes,” “anticipated,” “plans” and “expects,” and similar expressions, are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Such statements include, but are not limited to, statements about the terms, expected proceeds, use of proceeds and closing of the offering. Factors that could cause or contribute to such differences include, an inability to duplicate the clinical results demonstrated in clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company’s potential products, inability to raise the necessary capital and the risk factors set forth from time to time in CEL-SCI’s filings with the Securities and Exchange Commission, including but not limited to its report on Form 10-K for the year ended September 30, 2017. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

* LEAPS is an investigational technology, currently in preclinical development. LEAPS has not been licensed or approved for sale, barter or exchange anywhere in the world.

** Multikine (Leukocyte Interleukin, Injection) is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with the Company’s future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or any other regulatory agency. Similarly, its safety or efficacy has not been established for any use. Moreover, no definitive conclusions can be drawn from the early-phase, clinical-trials data involving the investigational therapy Multikine. Further research is required, and early-phase clinical trial results must be confirmed in the Phase 3 clinical trial of this investigational therapy that is in progress.